

Table 7.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1999 to 2008
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	220	305	305	375	344	420	343	293	261	213
Tx with Antirejection Treatments	57	65	45	43	61	59	46	32	33	16
Antibodies										
Any in Category	75.4%	53.8%	60.0%	48.8%	65.6%	59.3%	76.1%	68.8%	72.7%	43.8%
Atgam/NRATG/NRATS	1.8%	1.5%	2.2%	0.0%	3.3%	0.0%	0.0%	0.0%	0.0%	0.0%
OKT3	63.2%	35.4%	26.7%	25.6%	13.1%	15.3%	13.0%	15.6%	12.1%	12.5%
Thymoglobulin	22.8%	21.5%	33.3%	30.2%	45.9%	44.1%	63.0%	59.4%	63.6%	31.3%
Zenapax	1.8%	1.5%	2.2%	2.3%	6.6%	0.0%	4.3%	3.1%	3.0%	12.5%
Simulect	0.0%	4.6%	4.4%	0.0%	4.9%	0.0%	2.2%	3.1%	0.0%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	27.9%	8.5%	6.5%	3.1%	6.1%	0.0%
Corticosteroids										
Any in Category	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	68.8%	84.8%	87.5%
Steroids	84.2%	87.7%	86.7%	90.7%	68.9%	79.7%	63.0%	68.8%	84.8%	87.5%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.